BioXcel Therapeutics, Inc. has completed the sale of its assets to Teva Pharmaceuticals International GmbH as part of its Chapter 11 bankruptcy proceedings. This significant transaction, which includes key neuroscience assets, underscores the company's transition into a liquidation phase following its financial struggles.

On October 30, 2026, BioXcel announced that it had finalized the sale, which includes rights to its products IGALMI® and BXCL501, along with related intellectual property and regulatory filings. The deal was valued at $57.5 million in upfront cash, with potential additional payments based on future milestones related to product approvals and sales.

Background

BioXcel Therapeutics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a company based in New Haven, Connecticut. The firm specializes in developing innovative therapies for neuropsychiatric disorders. Previously traded on the Nasdaq under the ticker BTAI, BioXcel's stock is now listed on the OTC Pink Marketplace following its suspension from Nasdaq on September 8, 2026.

What the Filing Says

According to the recent SEC filing (accession number 0001104659-26-120737), the sale was approved by the U.S. Bankruptcy Court on October 21, 2026, following a bidding process where no other qualifying bids were received. The court's order allowed for the sale of substantially all the Debtors' assets to Teva, which will help facilitate the wind-down of BioXcel's operations.

Impact

This sale affects various stakeholders, including employees, creditors, and investors. The termination of key executives, including the Chief Executive Officer and other senior officers, signals a significant restructuring within the company. The transition to a new leadership structure, with Samir Saleem taking over as President and Secretary, indicates a shift in focus towards managing the liquidation process.

What's Next

The filing indicates that BioXcel will change its name to BX Liquidation, Inc., as part of its planned wind-down and liquidation strategy. This name change is expected to be formalized with the filing of a Certificate of Amendment in November 2026. The future of the company now hinges on the successful execution of this liquidation process and the potential recovery of funds for creditors.